Lupin gets USFDA nod for Kidney disease drug

Sevelamer Carbonate Tablets, 800 mg, are indicated for chronic kidney disease on dialysis.

81
Medicine Tablets
Picture: Pixabay

Last Updated on January 27, 2021 by The Health Master

Lupin has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children six years of age and older with chronic kidney disease on dialysis.

Sevelamer Carbonate Tablets (RLD: Renvela) had estimated annual sales of $348 million in the US (IQVIA MAT September 2020).


Also read | Zydus Cadila gets USFDA nod for Thyroid drug

Also read | Alembic receives USFDA approval for generic Midodrine HCL tablets

Also read | Caplin Steriles gets USFDA nod for generic Argatroban injection


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading